Molekylarbiologiske markører ved testikkelkreft
- Prosjektnummer
- 911980
- Ansvarlig person
- Olav Dahl
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Åpen prosjektstøtte
- Helsekategori
- Cancer
- Forskningsaktivitet
- 4. Detection and Diagnosis
Pasienter avgir blodprøver i forbindelse med behandling eller kontroll.
Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study.
Front Med (Lausanne) 2020;7():162. Epub 2020 apr 29
PMID: 32411717
Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer.
Adv Radiat Oncol 2020 May-Jun;5(3):396-403. Epub 2019 des 9
PMID: 32529133
Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version.
Acta Oncol 2020 Sep;59(9):1016-1023. Epub 2020 jun 23
PMID: 32574087
Quantitative PCR Measurement of miR-371a-3p and miR-372-p Is Influenced by Hemolysis.
Front Genet 2019;10():463. Epub 2019 mai 22
PMID: 31191602
Rationale for combination of radiation therapy and immune checkpoint blockers to improve cancer treatment.
Acta Oncol 2019 Jan;58(1):9-20. Epub 2019 jan 11
PMID: 30632870
The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018.
Acta Oncol 2019 Jan;58(1):1-8. Epub 2019 jan 30
PMID: 30698061
Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016.
Clin Colorectal Cancer 2019 03;18(1):e96-e103. Epub 2018 okt 16
PMID: 30415990
B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
Ann Intern Med 2019 05 07;170(9):585-593. Epub 2019 apr 2
PMID: 30934066
Optic nerve constraints for carbon ion RT at CNAO - Reporting and relating outcome to European and Japanese RBE.
Radiother Oncol 2019 Nov;140():175-181. Epub 2019 jul 13
PMID: 31310888
Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
Acta Oncol 2018 Aug;57(8):1075-1083. Epub 2018 jan 31
PMID: 29384420
No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease.
Brain 2018 Jan 24. Epub 2018 jan 24
PMID: 29373637
Rare genetic variation in mitochondrial pathways influences the risk for Parkinson's disease.
Mov Disord 2018 Oct;33(10):1591-1600. Epub 2018 sep 5
PMID: 30256453
A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer.
Sci Rep 2018 Apr 18;8(1):6157. Epub 2018 apr 18
PMID: 29670141
Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer.
Oncotarget 2017 Oct 20;8(50):87837-87847. Epub 2017 sep 23
PMID: 29152124
Risk of carotid blowout after reirradiation with particle therapy.
Adv Radiat Oncol 2017 Jul-Sep;2(3):465-474. Epub 2017 jul 6
PMID: 29114615
Linear energy transfer distributions in the brainstem depending on tumour location in intensity-modulated proton therapy of paediatric cancer.
Acta Oncol 2017 Jun;56(6):763-768. Epub 2017 apr 19
PMID: 28423966
Multimodal therapy is feasible in elderly anal cancer patients.
Acta Oncol 2017 Jan;56(1):81-87. Epub 2016 nov 3
PMID: 27808666
Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.
PLoS One 2016;11(8):e0161226. Epub 2016 aug 18
PMID: 27536947
Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome.
JCI Insight 2016 Dec 22;1(21):e89376. Epub 2016 des 22
PMID: 28018972
CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer.
Tumour Biol 2016 Jun;37(6):7441-52. Epub 2015 des 17
PMID: 26678887
LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Acta Oncol 2016 Dec;55(12):1425-1433. Epub 2016 jul 20
PMID: 27435662
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA).
Ann Oncol 2016 Jul;27(7):1299-304. Epub 2016 apr 6
PMID: 27052649
[Treatment for stage I-testicular cancer should be assessed individually].
Tidsskr Nor Laegeforen 2015 Aug 25;135(15):1340-1. Epub 2015 aug 25
PMID: 26315230
Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols.
Acta Oncol 2015 Apr;54(4):493-9. Epub 2014 sep 5
PMID: 25192551
B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.
PLoS One 2015;10(7):e0129898. Epub 2015 jul 1
PMID: 26132314
Twenty-five years with adjuvant chemotherapy for colon cancer--a continuous evolving concept.
Acta Oncol 2015 Jan;54(1):1-4. Epub 2014 sep 29
PMID: 25263079
Validity of Norwegian Rectal Cancer Registry data at a major university hospital 1997-2005.
Acta Oncol 2015 Nov;54(10):1723-8. Epub 2015 apr 23
PMID: 25904461
Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010.
Acta Oncol 2015 Nov;54(10):1714-22. Epub 2015 apr 30
PMID: 25924970
Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer.
Acta Oncol 2015 Apr;54(4):470-9. Epub 2014 sep 17
PMID: 25227897
Medikamentell kreftbehandling. Cytostatikaboken. 1-661
Univ. i Oslo, Med Fak, Inst for Klinisk Medisin, Avd for farmakologi, 8. utg. 2016
Kreftbiologi og medikamentell terapi. Kap 1, 13-46.
Medikamentell Kreftbehandling. Cytostatikaboken 2016.
Medikamentell kreftbehandling. Kap. 2 , 47-56.
Medikamentell Kreftbehandling. Cytostatikaboken 2016
Bivirkninger. Kap. 4, 67-97.
Medikamentell Kreftbehandling. Cytostatikaboken 2016
Metabolske forstyrrelser ved kreft. Kap. 7, 141-152.
Medikamentell Kreftbehandling. Cytostatikaboken 2016
Gastrointestinal kreft. Kap. 28, 481-499.
Medikamentell Kreftbehandling. Cytostatikaboken 2016
Kreft i nyre, urinveier og prostata. Kap. 31, 528-541.
Medikamentell Kreftbehandling. Cytostatikaboken 2016
Cancer testis. Kap. 32, 542-551.
Medikamentell Kreftbehandling. Cytostatikaboken 2016
Prognostic biomarkers in stage II and III colorectal cncer: A study with focus on microRNAs and S100A4
- Disputert:
- juni 2018
- Hovedveileder:
- Olav Dahl
Molecular and clinicopathological factors in colorectal cancer with emphasis on prognostic and predictive factors for survival
- Disputert:
- november 2016
- Hovedveileder:
- Olav Dahl
- Ole Johan Halvorsen Prosjektdeltaker
- Helge Ræder Prosjektdeltaker
- Nina Benedikte Rosenlund Prosjektdeltaker
- Mette Pernille Myklebust Medveileder
- Olav Dahl Prosjektleder
- Torgrim Tandstad Prosjektdeltaker
- Carl W. Langberg Prosjektdeltaker
- Hege Sagstuen Haugnes Prosjektdeltaker
- Winfried Kurt Rüger Prosjektdeltaker
- Peder Gjengstø Prosjektdeltaker
- Marianne Brydøy Prosjektdeltaker
- Åsa Karlsdottir Prosjektdeltaker
- Haris Causevic Prosjektdeltaker
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest